• Survival time [ Designated as safety issue: No ]
• Time to disease progression [ Designated as safety issue: No ]
• Confirmed response rate (complete response and partial response) [ Designated as safety issue: No ]
• Microvascular density and VEGF expression as assessed by IHC [ Designated as safety issue: No ]
• Plasma VEGF levels at baseline, 9 weeks, and at progression [ Designated as safety issue: No ]
• Immunologic parameters [ Designated as safety issue: No ]
• MGMT (O-6-methylguanine-DNA methyltransferase) [ Designated as safety issue: No ]

• Survival time
• Time to disease progression
• Confirmed response rate (complete response and partial response)
• Microvascular density and VEGF expression as assessed by IHC
• Plasma VEGF levels at baseline, 9 weeks, and at progression
• Immunologic parameters
• MGMT (O-6-methylguanine-DNA methyltransferase)

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Giving everolimus together with temozolomide may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving everolimus together with temozolomide works in treating patients with stage IV melanoma that cannot be removed by surgery

OBJECTIVES:

Primary

• Estimate the 9-week progression-free survival rate for patients with stage IV malignant melanoma treated with everolimus and temozolomide.

Secondary

• Evaluate overall survival time.
• Evaluate time to disease progression.
• Assess the toxicity profile of the combination of everolimus and temozolomide in patients with stage IV malignant melanoma.
• Assess the clinical benefit rate (i.e., stable disease, partial remission, and complete response rates).
• Describe the impact of therapy on parameters of angiogenesis and immunity (systemic and tumor microenvironment).

OUTLINE: This is a multicenter study.

Patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, 22-26, and 29-33 and oral temozolomide once a day on days 8-12 for course 1 only. For course 2 and all subsequent courses, patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, and 22-26 and oral temozolomide once a day on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

All patients undergo blood sample collection periodically for correlative studies. Samples are analyzed for relative numbers of T, B, and NK cells via flow cytometry, quantitative immunoglobulin levels (IgG, IgM, and IgA), Tetramer/ELISPOT CTL frequencies to CMV/EBV immunodominant antigens, V beta T cell spectratyping, and VEGF levels via ELISA.

After completion of study treatment, patients are followed every 8 weeks.

• Drug: everolimus
• Drug: temozolomide
• Genetic: reverse transcriptase-polymerase chain reaction
• Other: flow cytometry
• Other: immunohistochemistry staining method
• Other: immunologic technique

DISEASE CHARACTERISTICS:

• Histologically confirmed melanoma with manifestations of metastatic disease.

• Unresectable stage IV malignant melanoma with measurable disease

  • Measurable disease defined as at least one lesion with the longest diameter measured as ≥ 20 mm by CT scan or MRI scan OR ≥ 10 mm by spiral CT
• No previously untreated or unstable active brain metastases within the past 3 months
• No known standard therapy for this disease that is potentially curative or proven capable of extending life expectancy

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Life expectancy ≥ 12 weeks
• ANC ≥ 1,500/μL
• Platelet count ≥ 100,000/μL
• Hemoglobin ≥ 9.0 g/dL
• Alkaline phosphatase ≤ 3 times institutional upper limit of normal (ULN)
• Creatinine ≤ 1.5 times ULN
• AST ≤ 3 times ULN
• INR ≤ 1.5
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients and their partners must use effective contraception
• Able to return to a NCCTG institution for follow-up
• Able to forego foods high in fat content 2 hours prior to and 2 hours after administration of everolimus therapy
• Able to provide blood samples for research purposes
• No hypersensitivity to temozolomide, dacarbazine, or any analog of sirolimus
• No history of malignancy within the past 5 years except for basal cell or squamous cell carcinoma of the skin treated with local resection only
• No immunosuppression from any cause, including known HIV infection or chronic immunosuppressive therapy
• No impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome)

• No serious medical condition that may make it unsafe for a patient to enroll in study, including any of the following:

  • Severely impaired lung function (FEV1 < 1 liter), unstable angina pectoris (ongoing symptoms), ongoing symptomatic congestive heart failure (i.e., NYHA class I-IV) refractory to appropriate therapy, or myocardial infarction within the past 6 months, or serious uncontrolled cardiac arrhythmia
  • Uncontrolled diabetes in spite of optimal therapy (i.e., a history of fasting serum glucose > 150 mg/dL)
  • Any active (acute or chronic) or uncontrolled infection/disorders
  • Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the study treatment
  • Liver disease (i.e., uncompensated cirrhosis or active hepatitis with elevated liver enzymes)
• No bleeding diathesis
• No concurrent severe condition that would make it undesirable for the patient to participate in this trial or that would jeopardize compliance with the trial

PRIOR CONCURRENT THERAPY:

• Must have recovered from effects of prior antineoplastic therapy
• At least 4 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas)
• At least 4 weeks since prior immunotherapy
• At least 4 weeks since prior biologic therapy
• At least 4 weeks since prior radiosurgery
• At least 4 weeks since prior investigational therapy for melanoma
• No prior small bowel resection that may significantly alter the absorption of everolimus
• No prior sirolimus or its analogues
• No prior radiotherapy to > 30% of bone marrow
• No concurrent drugs that may induce CYP3A4 activity
• No concurrent warfarin
• No concurrent grapefruit or grapefruit juice
• No concurrent use or planned use of vaccines containing live virus